BioCentury
ARTICLE | Finance

Curbed enthusiasm

Why tempered investor enthusiasm doesn't mean the biotech bull is over

January 4, 2016 8:00 AM UTC

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets.

Nobody is calling an end to the biotech bull market, but volatility is the key word due to election year politics that will feature drug pricing as a central talking point, the sour performance of biotechs that tapped the markets in 2015, and an exodus of crossover investors that helped about 20 companies go public. ...